Black men are 70% more likely to become diagnosed with prostate cancer as all other men and more than twice as likely to die from this disease. However, diverse patient enrollment in prostate cancer clinical trials may make a difference in reducing this racial disparity. PHEN Survivor Network Member Art Cain is one such man […]
PHEN’s Clinical Trials Rally’s approach of educating Black prostate cancer patients about clinical trials, as well as strategic partnerships with pharmaceutical companies to amplify this message, is contributing to greater diversity among clinical trial participants. In addition to Pfizer’s TALAPRO-2 clinical trial featured in FDA approved post, PHEN also supported its TALAPRO-3 trial. Pfizer reported that they […]
